Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Factors that influence the bleeding phenotype in severe hemophilic patients.

Rendo P, Shafer F, Korth-Bradley JM, Sivamurthy K, Korin J.

Blood Coagul Fibrinolysis. 2013 Oct;24(7):683-90. doi: 10.1097/MBC.0b013e3283614210. Review.

PMID:
24056291
2.

Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile.

Santagostino E, Mancuso ME, Tripodi A, Chantarangkul V, Clerici M, Garagiola I, Mannucci PM.

J Thromb Haemost. 2010 Apr;8(4):737-43. doi: 10.1111/j.1538-7836.2010.03767.x. Epub 2009 Jan 21.

3.

Hemophilia A and hemophilia B: focus on arthropathy and variables affecting bleeding severity and prophylaxis.

Escobar M, Sallah S.

J Thromb Haemost. 2013 Aug;11(8):1449-53. doi: 10.1111/jth.12317. Review.

4.

Defining severity of hemophilia: more than factor levels.

Pavlova A, Oldenburg J.

Semin Thromb Hemost. 2013 Oct;39(7):702-10. doi: 10.1055/s-0033-1354426. Epub 2013 Sep 11. Review.

PMID:
24026911
5.

Phenotypic heterogeneity in severe hemophilia.

van den Berg HM, De Groot PH, Fischer K.

J Thromb Haemost. 2007 Jul;5 Suppl 1:151-6.

6.

Inhibitor antibodies to factor VIII and factor IX: management.

Lusher JM.

Semin Thromb Hemost. 2000;26(2):179-88. Review.

PMID:
10919411
7.

Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia.

Schaub RG.

Biochem Pharmacol. 2011 Jul 15;82(2):91-8. doi: 10.1016/j.bcp.2011.03.015. Epub 2011 Mar 29. Review.

PMID:
21453683
8.

Hemophilia A in the third millennium.

Franchini M, Mannucci PM.

Blood Rev. 2013 Jul;27(4):179-84. doi: 10.1016/j.blre.2013.06.002. Epub 2013 Jun 28. Review.

PMID:
23815950
9.

Orthopaedic problems about the ankle in hemophilia.

Rodriguez-Merchan EC.

J Foot Ankle Surg. 2012 Nov-Dec;51(6):772-6. doi: 10.1053/j.jfas.2012.06.005. Epub 2012 Jul 10. Review.

PMID:
22785085
10.

Tailored versus standard dose prophylaxis in children with hemophilia A.

Santoro C, Baldacci E, Mercanti C, Mazzucconi MG.

Semin Thromb Hemost. 2013 Oct;39(7):711-22. doi: 10.1055/s-0033-1354419. Epub 2013 Sep 10. Review.

PMID:
24022808
11.

Management of joint bleeding in hemophilia.

Simpson ML, Valentino LA.

Expert Rev Hematol. 2012 Aug;5(4):459-68. Review.

PMID:
22992238
12.

Prothrombin complex concentrate (Konyne) in the treatment of hemophilic patients with factor VIII inhibitors.

Abildgaard CF, Britton M, Harrison J.

J Pediatr. 1976 Feb;88(2):200-5.

PMID:
1249680
13.

Defining the impact of hemophilia: the Academic Achievement in Children with Hemophilia Study.

Shapiro AD, Donfield SM, Lynn HS, Cool VA, Stehbens JA, Hunsberger SL, Tonetta S, Gomperts ED; Academic Achievement in Children with Hemophilia Study Group.

Pediatrics. 2001 Dec;108(6):E105.

PMID:
11731632
14.

Treatment strategies in children with hemophilia.

Petrini P.

Paediatr Drugs. 2002;4(7):427-37. Review.

PMID:
12083971
15.

Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management.

Mahasandana C, Patharathienskul D, Suvatte V.

Southeast Asian J Trop Med Public Health. 1993;24 Suppl 1:106-12.

PMID:
7886549
16.
17.
18.

Paradoxical hyperfibrinolysis is associated with a more intensely haemorrhagic phenotype in severe congenital haemophilia.

Grünewald M, Siegemund A, Grünewald A, Konegan A, Koksch M, Griesshammer M.

Haemophilia. 2002 Nov;8(6):768-75.

PMID:
12410645
19.

Human factor IX corrects the bleeding diathesis of mice with hemophilia B.

Kung SH, Hagstrom JN, Cass D, Tai SJ, Lin HF, Stafford DW, High KA.

Blood. 1998 Feb 1;91(3):784-90.

20.

Recent advances in hemophilia.

Tann G.

Southeast Asian J Trop Med Public Health. 1979 Jun;10(2):218-28.

PMID:
524146

Supplemental Content

Support Center